Social News
Written by: Lao Minyi
2021-01-20 18:44
Last update date: 2021-01-20 18:45
The Hong Kong Institute of Hospital Pharmacists stated today (20th) that it had analyzed preliminary data from the Phase III clinical trial of the Coxing New Coronary Pneumonia Vaccine published online by the Brazilian government and found that the 100% prevention of moderate to severe hospital admission data is not statistically established. , And the overall efficiency is low.
The committee recommends that the government reconsider whether the Kexing vaccine should be used for elderly people aged 60 or over; when the safety and effectiveness of the third phase of clinical research is peer reviewed (Peer Review), it can be used for the age group 59 or younger person.
▼ Kexing vaccine needs seven steps from the laboratory to the market▼
+9
+9
+9
The Hong Kong Institute of Hospital Pharmacists pointed out that earlier media reports from Coxinghe had indicated that Coxing vaccine can prevent 100% of moderate to severe infections from being admitted to the hospital. However, the Brazilian Drug Administration (ANVISA) indicated that there is not enough data to draw conclusions on the effectiveness, or that it can prevent Moderate to severe infections were admitted to the hospital because there were only 7 cases of moderate and severe infections in the placebo group in the third phase of the study, which is not statistically valid.
The association explained that although the third phase of the Brazil study recruited elders 60 years or older, only 600 people were recruited. Among them, only 413 completed two vaccinations, which did not meet the 1,260 people required to participate in clinical trials to establish a vaccine. Effectiveness and safety in the elderly.
According to official figures, 2 of the 186 vaccinated elderly people were infected, and 3 of the 176 placebo elderly people were infected with the coronavirus.
In addition, the association stated that although the Phase III clinical research data of Kexing has not been peer-reviewed, the Brazilian government has confirmed the above mentioned. In addition, the Phase III clinical research of Turkey and Indonesia did not involve persons aged 60 or above, which clearly shows that the current Kexing's new crown pneumonia vaccine cannot obtain data support for the elderly.
▼Protection rate side effects of Kexing, BioNTECH Fosun, AstraZeneca ▼
+2
+2
+2
Advocate Kexing vaccine for people aged 59 or younger
Therefore, the committee recommended that Kexing vaccine be used for people aged 59 or younger, and those aged 60 or above should consider other vaccines with higher protection rates, and refer to the British practice to package the 195 vials of the vaccine jointly developed by Fosun and BioNTech. Disassemble a smaller number of packages for inoculation of residential care homes for the elderly
The association also urged the Hong Kong government to contact AstraZeneca to expedite the arrival time of the new crown vaccine in Hong Kong, and then contact Sinopharm to obtain clinical trial safety and effectiveness data standards, and strive to provide vaccines to Hong Kong; and proactively contact other vaccine manufacturers such as Janssen ( Zanchen) and Novavax (Novavax) plan to purchase vaccines.
New crown vaccine | Kexing said the two injections are three weeks apart, the effective rate rises, experts say the theory is established but the number of people is small
New Crown Vaccine｜The Food and Health Bureau said that "you see" the vaccination date of other pharmaceutical companies will be finalized later
New Crown Vaccine | He Boliang advocates to follow the example of the UK's public vaccine approval information to ensure the quality of pharmaceutical companies
New Crown Vaccine｜Expert Committee supports the introduction of BioNTech vaccine to Hong Kong from the end of February
BioNTech vaccine 29 people died after vaccination in Norway
01News
New crown pneumonia new crown vaccine
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/LXJQLIHEEJDHBNVN45ZLQLAMJY.jpg)